» Articles » PMID: 6869479

Ocular Toxicity of Fluorouracil After Vitrectomy

Overview
Journal Am J Ophthalmol
Specialty Ophthalmology
Date 1983 Jul 1
PMID 6869479
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

The retinal and corneal toxicity of fluorouracil in the rabbit eye after lensectomy and vitrectomy depended on both the dosage and the frequency of intraocular injection and was reversible at certain dosages. All eyes in Group 1 (1.25 mg of fluorouracil every 12 hours for four days and then every 24 hours for three days) had opaque corneas by three days; these did not clear for four weeks. Histologic studies showed loss of photoreceptor outer segments and loss of ribosomes in all the retinal cells examined. The electroretinographic b-wave decreased to 0% of the baseline value (no b-wave), and did not recover after three weeks. In Group 2 eyes (1.25 mg of fluorouracil every 24 hours for seven days), corneal opacification increased to a maximum after two weeks and gradually decreased by four weeks. The electroretinographic b-wave diminished to 9.6% of the baseline value at two weeks but later recovered to 62.5% of the baseline value at three weeks. Histologic studies showed loss of photoreceptor outer segments and ribosomes at nine days; both returned to near normal after five weeks. Clinical, electrophysiologic, and histologic studies showed no toxicity in Group 3 eyes (0.5 mg of fluorouracil every 24 hours for seven days). This dosage of fluorouracil exerts a significant antiproliferative effect on injected retinal pigment epithelial cells and is well tolerated by the rabbit eye.

Citing Articles

Combined 5-Fluorouracil and Low Molecular Weight Heparin for the Prevention of Postoperative Proliferative Vitreoretinopathy in Patients With Retinal Detachment: A Meta-Analysis.

Chen C, Chen P, Liu X, Li H Front Med (Lausanne). 2021; 8:790460.

PMID: 34917641 PMC: 8669826. DOI: 10.3389/fmed.2021.790460.


A novel lipid prodrug strategy for sustained delivery of hexadecyloxypropyl 9-[2-(phosphonomethoxy)ethyl]guanine (HDP-PMEG) on unwanted ocular proliferation.

Chen M, Hou J, Tan G, Xie P, Freeman W, Beadle J Drug Deliv. 2017; 24(1):1703-1712.

PMID: 29115885 PMC: 8241053. DOI: 10.1080/10717544.2017.1399303.


The impact of octreotide in experimental proliferative vitreoretinopathy.

Evren O, Turgut B, Celiker U, Ates K Indian J Ophthalmol. 2013; 61(3):109-14.

PMID: 23514645 PMC: 3665038. DOI: 10.4103/0301-4738.109380.


Evaluation of 5-fluorouracil released from a foldable capsular vitreous body in vitro and in vivo.

Zheng H, Wang Z, Wang P, Liu Y, Jiang Z, Gao Q Graefes Arch Clin Exp Ophthalmol. 2011; 250(5):751-9.

PMID: 22119880 DOI: 10.1007/s00417-011-1862-y.


Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced 'chemo-fog'.

Raffa R, Tallarida R J Clin Pharm Ther. 2010; 35(3):249-55.

PMID: 20831527 PMC: 3249620. DOI: 10.1111/j.1365-2710.2009.01086.x.